View in EDS

Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Saved in:
Bibliographic Details
Title: Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
Authors: Furman RR; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY., Wierda WG; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Patten PEM; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.; Department of Haematology, King's College Hospital, London, United Kingdom., Chaves JM; Northwest Medical Specialties, Tacoma, WA., Brown JR; Dana-Farber Cancer Institute, Boston, MA., Munir T; Department of Haematology, St James's University Hospital, Leeds, United Kingdom., Martin P; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY., Awan FT; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX., Stephens DM; Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC., Ghia P; Università Vita-Salute San Raffaele, Milan, Italy.; Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan, Italy., Barrientos JC; Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY., Patel K; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA., Woyach JA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., de Borja M; AstraZeneca, Mississauga, ON, Canada., Wang MH; AstraZeneca, South San Francisco, CA., Jain N; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., O'Brien SM; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA., Byrd JC; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Source: Blood advances [Blood Adv] 2026 Jun 09; Vol. 10 (11), pp. 3931-3941.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Clinical Trial, Phase I
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41915892
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Furman+RR%22">Furman RR</searchLink>; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.<br /><searchLink fieldCode="AU" term="%22Wierda+WG%22">Wierda WG</searchLink>; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Patten+PEM%22">Patten PEM</searchLink>; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.; Department of Haematology, King's College Hospital, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Chaves+JM%22">Chaves JM</searchLink>; Northwest Medical Specialties, Tacoma, WA.<br /><searchLink fieldCode="AU" term="%22Brown+JR%22">Brown JR</searchLink>; Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Munir+T%22">Munir T</searchLink>; Department of Haematology, St James's University Hospital, Leeds, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Martin+P%22">Martin P</searchLink>; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY.<br /><searchLink fieldCode="AU" term="%22Awan+FT%22">Awan FT</searchLink>; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Stephens+DM%22">Stephens DM</searchLink>; Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Ghia+P%22">Ghia P</searchLink>; Università Vita-Salute San Raffaele, Milan, Italy.; Comprehensive Cancer Center, IRCCS Ospedale San Raffaele, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Barrientos+JC%22">Barrientos JC</searchLink>; Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.<br /><searchLink fieldCode="AU" term="%22Patel+K%22">Patel K</searchLink>; Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Woyach+JA%22">Woyach JA</searchLink>; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22de+Borja+M%22">de Borja M</searchLink>; AstraZeneca, Mississauga, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Wang+MH%22">Wang MH</searchLink>; AstraZeneca, South San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Jain+N%22">Jain N</searchLink>; Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22O'Brien+SM%22">O'Brien SM</searchLink>; Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA.<br /><searchLink fieldCode="AU" term="%22Byrd+JC%22">Byrd JC</searchLink>; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2026 Jun 09; Vol. 10 (11), pp. 3931-3941.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41915892
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2025018310
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3931
    Titles:
      – TitleFull: Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Furman RR
      – PersonEntity:
          Name:
            NameFull: Wierda WG
      – PersonEntity:
          Name:
            NameFull: Patten PEM
      – PersonEntity:
          Name:
            NameFull: Chaves JM
      – PersonEntity:
          Name:
            NameFull: Brown JR
      – PersonEntity:
          Name:
            NameFull: Munir T
      – PersonEntity:
          Name:
            NameFull: Martin P
      – PersonEntity:
          Name:
            NameFull: Awan FT
      – PersonEntity:
          Name:
            NameFull: Stephens DM
      – PersonEntity:
          Name:
            NameFull: Ghia P
      – PersonEntity:
          Name:
            NameFull: Barrientos JC
      – PersonEntity:
          Name:
            NameFull: Patel K
      – PersonEntity:
          Name:
            NameFull: Woyach JA
      – PersonEntity:
          Name:
            NameFull: de Borja M
      – PersonEntity:
          Name:
            NameFull: Wang MH
      – PersonEntity:
          Name:
            NameFull: Jain N
      – PersonEntity:
          Name:
            NameFull: O'Brien SM
      – PersonEntity:
          Name:
            NameFull: Byrd JC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 06
              Text: 2026 Jun 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1